Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07524855 · ClinicalTrials.gov registry record · Phase 1
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Halda Therapeutics OpCo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT07524855 is a Phase 1 study that is actively recruiting participants, run by Halda Therapeutics OpCo. The registered enrollment target is 33 participants.
The verdict
NCT07524855, a Phase 1 study, is actively recruiting participants, sponsored by Halda Therapeutics OpCo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
Interventions
- DRUG HLD-0117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07524855
The ClinicalTrials.gov registry entry for NCT07524855 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halda Therapeutics OpCo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HLD-0117 is the first listed.
NCT07524855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07524855 about?
NCT07524855 is a clinical study titled "A Study of HLD-0117 in Patients With Metastatic Breast Cancer". Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
What is the current status of trial NCT07524855?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2026-04-09. Estimated completion is 2028-04-30.
What interventions are being tested in trial NCT07524855?
The interventions under investigation include: HLD-0117 (DRUG).
Who is sponsoring clinical trial NCT07524855?
This trial is sponsored by Halda Therapeutics OpCo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.